Forest Laboratories

1. IP Boutique Darby & Darby To Close Down

Friday, Mar 12, 2010

Boutique intellectual property firm Darby & Darby PC on Friday announced plans to dissolve, following the recent departure of several high-profile partners.

2. Health Cos. Bear Brunt Of State AGs' Antitrust Focus

Thursday, Jan 21, 2010

Antitrust enforcers in states' attorney general offices raked in settlements and awards valued at nearly $371 million in 2009, with the lion's share of that haul coming from efforts to crack down on alleged pricing abuses and collusion among health care and pharmaceutical companies.

3. Kirkland & Ellis Patent Pro Joins Quinn Emanuel

Thursday, Jan 14, 2010

Patent litigator Peter Armenio has joined the New York office of international law firm Quinn Emanuel Urquhart Oliver & Hedges LLP from rival Kirkland & Ellis LLP.

4. FDA Warns Against Bystolic For Heart Patients

Thursday, Jan 07, 2010

Researchers at the U.S. Food and Drug Administration are urging the agency not to approve Forest Laboratories Inc.’s hypertension drug Bystolic for use with heart failure patients.

5. Lupin Gets Namenda License In Forest Settlement

Tuesday, Dec 22, 2009

Lupin Ltd. has received a license to begin selling a generic version of Forest Laboratories Inc.'s Namenda about four months before a patent for the lucrative Alzheimer's drug expires, as part of a settlement between the two companies, the Indian pharmaceutical maker said Monday.

6. Celexa, Lexapro Deal Covers Civil Claims Only

Monday, Nov 09, 2009

Forest Laboratories Inc. and the U.S. Department of Justice have struck a deal to settle civil claims stemming from investigations into the marketing of antidepressants Celexa and Lexapro and a hypothyroidism treatment, but the pact does not cover an ongoing probe into possible criminal violations related to the drugs.

7. Infosint Seeks $43M Damages In Citalopram Suit

Friday, Nov 06, 2009

Infosint SA has asked a judge to increase a $15 million reasonable royalty award that a jury issued for Lundbeck A/S and Forest Laboratories Inc.'s alleged infringement of a patent for making the antidepressant citalopram, arguing that it should receive additional damages and interest totaling almost $43 million.

8. Jury Awards Infosint $15M In Lexapro Patent Fight

Monday, Oct 19, 2009

Lundbeck A/S and Forest Laboratories Inc. will have to pay Infosint SA a $15 million reasonable royalty award now that a federal jury has ruled that Infosint's patent for making the antidepressant citalopram is valid.

9. Sun Retreats From Alzheimer Drug Battle

Friday, Oct 16, 2009

Sun India Pharmaceuticals Inc. has backed off from marketing generic tablets of the lucrative Alzheimer's drug Namenda, becoming the latest manufacturer to surrender to Forest Laboratories Inc. in an ongoing patent battle.

10. Forest Settles Suit Over Celexa, Lexapro Kickbacks

Wednesday, Sep 30, 2009

Forest Laboratories Inc. has moved to settle a lawsuit brought by the U.S. Department of Justice and two whistleblowers accusing the company of bribing doctors to prescribe antidepressants Celexa and Lexapro and marketing the drugs for pediatric use without approval from the U.S. Food and Drug Administration.

11. Upsher-Smith, Others Exit Namenda Patent Case

Monday, Sep 14, 2009

A judge has signed off on a request to dismiss Upsher-Smith Laboratories Inc., Wockhardt Ltd., Amneal Pharmaceuticals LLC and Apotex Corp. from a patent suit that Forest Laboratories brought to protect the lucrative market for the Alzheimer's drug Namenda from generic competition.

12. Watson Pharma Ala. AWP Case Ends In Mistrial

Monday, Jul 13, 2009

An Alabama judge reportedly declared a mistrial on Monday in a trial for a lawsuit filed by the Alabama attorney general against Watson Pharmaceuticals Inc., accused of taking part in an industrywide scheme to bilk Medicaid by inflating drug prices.

13. Sun, Forest Reach Deal In Lexapro Patent Suit

Friday, Jul 10, 2009

Sun Pharmaceutical Industries Ltd. has reached a deal with Forest Laboratories Inc. to license several patents related to the antidepressant Lexapro, bringing an end to a long-running patent suit between the drugmakers.

14. Forest, Lundbeck Lose Bid To Limit Lexapro Claims

Wednesday, Jul 01, 2009

A federal judge has rejected the latest bid from H. Lundbeck A/S and its partner Forest Laboratories Inc. to pare down a patent dispute related to the antidepressant citalopram, ruling that a lone letter from one of the companies' suppliers did not yield enough evidence to drop part of Infosint SA's infringement claims.

15. Forest Derivative Appeal Halted As Sides Seek Deal

Tuesday, Jun 30, 2009

A federal appeals court has agreed to a further suspension in the appeal of a shareholder derivative suit alleging that certain Forest Laboratories Inc. executives misled shareholders about the company's main products, blockbuster antidepressant drugs Celexa and Lexapro, because the two sides are currently discussing “partial resolution” of the case.

16. Dueling Patents Partly Invalidated In Lexapro Row

Monday, Jun 01, 2009

In a blow to both sides battling over conflicting patents related to the antidepressant citalopram, a federal judge has found two claims of plaintiff Infosint SA's patent obvious but also invalidated the first claim of defendant H. Lundbeck A/S' patent after finding the company had suppressed or concealed its invention.

17. New Lexapro Class Action Can't Tag Onto MDL

Thursday, May 28, 2009

A federal judge has shot down a bid to consolidate a newly filed proposed class action with multidistrict litigation over Lexapro and Celexa, saying the new product liability lawsuit asserts allegations relating to Forest Laboratories Inc.'s marketing of the drugs, while the MDL relates only to damages for personal injuries arising from suicidality.

18. Ala. Scores $89M In Drug Co. Medicaid Fraud Case

Friday, May 22, 2009

The state of Alabama has struck an $89 million deal with six major drugmakers accused of overcharging the Alabama Medicaid Agency, including Sanofi-Aventis and Abbott Laboratories, in ongoing litigation alleging dozens of pharmaceutical companies artificially inflated their prices.

19. Forest Loses Bid To Limit Liability In Citalopram IP Suit

Thursday, May 07, 2009

In a patent infringement suit brought by Infosint SA over the antidepressant citalopram, a federal judge has refused to limit Forest Laboratories Inc.'s liability through a law meant to protect "innocent infringers" before they know about a patent.

20. Spoliation Hearing Granted In Lexapro Patent Suit

Wednesday, Apr 15, 2009

A federal district judge has granted a spoliation hearing to determine whether Forest Laboratories Inc. improperly destroyed key documents related to its infringement suit against Caraco Pharmaceutical Laboratories Ltd. over a patent for the depression treatment Lexapro.